FourThought Financial LLC Grows Holdings in Exact Sciences Co. (NASDAQ:EXAS)

FourThought Financial LLC grew its holdings in Exact Sciences Co. (NASDAQ:EXAS – Get Rating) by 97.5% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 2,400 shares of the medical research company’s stock after purchasing an additional 1,185 shares during the period. FourThought Financial LLC’s holdings in Exact Sciences were worth $78,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Signaturefd LLC increased its stake in Exact Sciences by 45.7% in the third quarter. Signaturefd LLC now owns 957 shares of the medical research company’s stock worth $31,000 after purchasing an additional 300 shares during the period. Householder Group Estate & Retirement Specialist LLC purchased a new stake in Exact Sciences in the third quarter worth $33,000. National Bank of Canada FI grew its position in shares of Exact Sciences by 72.6% during the 3rd quarter. National Bank of Canada FI now owns 1,189 shares of the medical research company’s stock worth $39,000 after buying an additional 500 shares in the last quarter. Northern Oak Wealth Management Inc. grew its position in shares of Exact Sciences by 33.8% during the 2nd quarter. Northern Oak Wealth Management Inc. now owns 1,585 shares of the medical research company’s stock worth $62,000 after buying an additional 400 shares in the last quarter. Finally, Wipfli Financial Advisors LLC bought a new position in shares of Exact Sciences during the 3rd quarter worth $62,000. Hedge funds and other institutional investors own 90.30% of the company’s stock.

Exact Sciences Stock Performance

Shares of NASDAQ EXAS opened at $63.44 on Friday. The company has a debt-to-equity ratio of 0.73, a current ratio of 2.38 and a quick ratio of 2.09. The business has a 50-day simple moving average of $65.30 and a two-hundred day simple moving average of $48.98. Exact Sciences Co. has a fifty-two week low of $29.27 and a fifty-two week high of $76.94.

Exact Sciences (NASDAQ:EXAS – Get Rating) last issued its quarterly earnings results on Tuesday, February 21st. The medical research company reported ($0.72) earnings per share for the quarter, topping the consensus estimate of ($0.90) by $0.18. The business had revenue of $553.00 million during the quarter, compared to the consensus estimate of $525.61 million. Exact Sciences had a negative return on equity of 19.76% and a negative net margin of 29.92%. The company’s quarterly revenue was up 16.7% on a year-over-year basis. During the same quarter last year, the company earned ($1.28) earnings per share. On average, equities analysts forecast that Exact Sciences Co. will post -2.76 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research firms have recently issued reports on EXAS. Raymond James downgraded Exact Sciences from an “outperform” rating to a “market perform” rating in a research report on Wednesday, January 18th. Benchmark increased their price target on Exact Sciences from $54.00 to $78.00 and gave the stock a “buy” rating in a research report on Wednesday. Cowen increased their price target on Exact Sciences from $56.00 to $76.00 and gave the stock an “outperform” rating in a research report on Wednesday, February 22nd. StockNews.com started coverage on Exact Sciences in a research report on Thursday. They set a “hold” rating on the stock. Finally, Credit Suisse Group reaffirmed a “neutral” rating and set a $70.00 price objective on shares of Exact Sciences in a research report on Wednesday, February 22nd. Five research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $74.14.

Insider Transactions at Exact Sciences

In other news, CEO Kevin T. Conroy sold 4,527 shares of the firm’s stock in a transaction dated Monday, February 13th. The stock was sold at an average price of $64.55, for a total value of $292,217.85. Following the completion of the transaction, the chief executive officer now directly owns 1,173,105 shares in the company, valued at $75,723,927.75. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. In other news, Director D Scott Coward sold 1,821 shares of the firm’s stock in a transaction dated Wednesday, February 15th. The stock was sold at an average price of $65.59, for a total value of $119,439.39. Following the completion of the transaction, the director now directly owns 26,493 shares in the company, valued at $1,737,675.87. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Kevin T. Conroy sold 4,527 shares of the firm’s stock in a transaction dated Monday, February 13th. The stock was sold at an average price of $64.55, for a total value of $292,217.85. Following the completion of the transaction, the chief executive officer now owns 1,173,105 shares of the company’s stock, valued at $75,723,927.75. The disclosure for this sale can be found here. Insiders sold a total of 62,126 shares of company stock worth $3,915,586 over the last three months. 1.30% of the stock is currently owned by insiders.

About Exact Sciences

(Get Rating)

EXACT Sciences Corp. is a cancer screening and diagnostics company. The firm focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer and Oncotype DX. The company was founded on February 10, 1995, and is headquartered in Madison, WI.